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Executive Summary
The Task Force on Improving Prescription Drugs for the Elderly was created by
Public Law 1997, Chapter 560, Part E.  Its charge was direct:  To determine and
recommend methods of improving access to prescription drugs for the elderly.
The Task Force met four times, and relied greatly on information provided by the
Department of Human Services, Bureau of Medical Services on population, drug usage
and program utilization rate estimates and projections.
The Task Force makes four recommendations:
1. Improve the public education and outreach efforts for the current Elderly Low-
cost Drug Program;
 
2. Direct the Department of Human Services to seek a Medicaid waiver from the
Health Care Financing Administration to provide Medicaid prescription drug
benefits for persons 62 years of age and over, whose income is up to 185% of
the federal poverty level.  The recommendation is flexible concerning the exact
percentage of the federal poverty level in order to approximate cost neutrality
achieved through the decrease in institutionalization costs resulting from
greater access to prescription drugs for the elderly;
 
3. Until the waiver is granted and the program under it takes effect, expand the
existing Elderly Low-cost Drug Program by increasing the income ceiling to
185% of the federal poverty level.  Because this recommendation was arrived
at before all the estimates and projections were available from the Bureau of
Medical Services, the Task Force may support an adjustment in this income
level and a shift to include additional medications if the benefits are greater as
indicated by the new information; and
 
4. Request that the Joint Standing Committee on Banking and Insurance, the
Joint Standing Committee on Health and Human Services and the Bureau of
Insurance work together to develop methods of providing financial assistance
or insurance coverage for prescription drugs for organ transplant patients in
this State.
I Introduction
A.  Inception of the study
During the First Regular and First Special Sessions of the 118th Legislature, the
Legislature and the Governor wrestled with issues concerning taxes on tobacco products,
improving the health of Maine citizens and whether and how those issues should be
connected.  Although much of the discussion and drafting centered in the Joint Standing
Committee on Health and Human Services, there was considerable floor debate as well.
Interim proposals concerning the prescription drugs for the elderly program included an
expansion of the existing program to extend Medicaid prescription drug coverage to elder
adults meeting age and income criteria (LD 1887, vetoed by the Governor).  When the
Legislature finally adjourned, Public Law 1997, Chapter 560 (LD 1904) created the Task
Force on Improving Access to Prescription Drugs for the Elderly.
B.  Task Force on Improving Access to Prescription Drugs for the Elderly
The Task Force on Improving Access to Prescription Drugs for the Elderly was
created in Public Law 1997, Chapter 560, Part E.  (See Appendix A.)  The Task Force
consists of nine members, three each appointed by the President of the Senate, the Speaker
of the House of Representatives and the Governor.  The three appointing authorities were
required to jointly select the Task Force Chair from the members.  Senator Chellie Pingree
was selected as chair.  See Appendix B for the list of members.
Although the effective date of Part E of Chapter 560 was September 19, 1997 and
the legislation required the first meeting to be convened no later than October 10, 1997,
because the appointment process was delayed, the Task Force did not begin meeting until
December 4, 1997.  Chapter 560 established the reporting date for the Task Force’s report
and legislative recommendations as January 15, 1998.  The Legislative Council extended
that reporting date to February 13, 1998.
The charge to the Task Force is direct:  To determine and recommend methods on
improving access to prescription drugs for the State’s elderly citizens.
C.  Study process
One of the first questions the Task Force faced was what does “improving access”
mean?  There was some discussion as to whether elderly citizens can adequately access
prescription drugs under the current program.  Another question faced by the Task Force
was what is the program lacking?  One concern is that the State is missing an opportunity
to provide medication crucial to keeping a large segment of the older population in the
workforce by not including more illnesses, conditions and medications in the program.  If
illnesses and conditions are treated earlier, better health and greater savings can be enjoyed
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in the future.  An evaluation of New York State’s EPIC program found significant savings
in acute care and institutionalization costs resulting from better access to prescription
drugs for the older population.  (EPIC Evaluation Report to the Governor and
Legislature: Maintaining Health, Dignity and Independence, 1987-1995)
The Task Force heard about specific and general inadequacies of the current
program.  For example, anti-rejection drugs needed by organ transplant patients are not
covered by the Elderly Low-cost Drug Program or Medicare.  There is apparently no
practical insurance coverage available in Maine for organ transplant patients, whose
prescription drugs bills run as high as $2,000 per month.  A social worker with the Maine
Medical Center informed the Task Force that more transplants were being provided to
more people, and that more recipients are in their 60s and 70s than ever before.  This
means a greater number of people will have extremely high prescription drug costs with
very few avenues of assistance open to them unless they are indigent.  (Medicaid and some
drug manufacturers’ programs provide coverage or assistance to low income transplant
patients.)  Another social worker from the Maine Medical Center explained the difficult
choices that many people face when their resources are insufficient to cover both
medications and other necessities.
The Task Force discussed several ways that the current program could be changed
to improve access:
· Better utilization of the current program, aided through better public education
and outreach about the availability of the program
· Expand eligibility for the program
· Increasing the income limitations
· Lowering the minimum age
· Expand the diagnoses -- and, hence, the medications -- covered
The Task Force requested the Department of Human Services, Bureau of Medical
Services to estimate the costs of improving access through the implementation of each
option.  The members developed their recommendations with deference to what is realistic
in terms of new costs to the State and the likelihood of additional funding from the federal
government.
Special thanks to Francis Finnegan and Robert Carroll of the Bureau of Medical Services
for crucial assistance in providing the Task Force with information about the Elderly Low-
cost Drug Program and projected costs and affected population estimates.
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II Background
A.  Current program
The current Low-cost Drugs for the Elderly Program is established in Title 22,
section 254 of the Maine Revised Statutes.  (See Appendix C.)  The Department of
Human Services is authorized to conduct a program to provide low-cost prescription and
non-prescription drugs, medication and medical supplies to disadvantaged, elderly
individuals.   The Commissioner has delegated the responsibility for administering the
program to the Bureau of Medical Services.  The Bureau of Medical Services also
administers the Medicaid program in Maine.  This connection is important in the
administration of the prescription drug program.
Eligibility status of individuals is determined by the State Tax Assessor pursuant to
Title 36, chapter 905 of the Maine Revised Statutes.  (See Appendix C.)  Application for a
“drug card” is made on a combined form that allows Maine residents to apply for the
property tax refund program, the rent refund program and the elderly low-cost drug
program simultaneously.  The Maine Revenue Services (formerly Bureau of Taxation)
processes all applications as if a person applying for one of the programs is applying for
all.  If an applicant meets the age and income requirements, a drug card is issued and
mailed to the applicant.  In calendar year 1996, the Bureau of Taxation processed 56,473
applications; 16,249 applicants were issued drug cards. The number of applications
processed in 1997 through November 26 was 44,168; 13,671 drug cards had been issued
by that date.
Age eligibility.  The age requirements for the Elderly Low-cost Drug Program are
tied to the Maine Residents Property Tax Program, specifically the definition of “elderly
household” in Title 36, section 6201.  To qualify, an applicant must  be either 62 years old
or part of a household where one person is at least 62 years old.  An applicant who is
disabled qualifies if at least 55 years old and receiving federal disability payments; if
married, one spouse must be at least 55 years old and both must be receiving federal
disability payments.
Income eligibility.  The income limitations are also tied to the Maine Residents
Property Tax Program.  Title 36, section 6206 sets income ceilings for single-member
elderly households and elderly households with 2 or more members.  The statutory
amounts were last set by the Legislature in 1987.  The State Tax Assessor is required to
determine the “household income eligibility adjustment factor” every year to determine the
appropriate increase in the income limitations.  The State Tax Assessor ties the adjustment
factor to the cost of living figure issued by the federal Social Security Administration each
October.  The income levels are multiplied by the adjustment factor, and the result
rounded to the nearest $100, to arrive at the applicable income limitation for that year.
The income limitation is increased by 25% for households that have spent at least 40% of
the household income on unreimbursed direct medical expenses for prescription drugs.
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For 1996, the income limitations were as follows:
Household size Maximum income
Claimant lives alone $10,300
Claimant married or with
dependents
$12,700
Claimant lives alone, at least
40% of income spent on
prescription drugs
$12,875
Claimant married or with
dependents, at least 40% of
income spent on prescription
drugs
$15,875
Diagnoses.  The Elderly Low-cost Drug Program pays for drugs to treat illnesses.
The law specifically requires the inclusion of prescription drugs used for the treatment of
obstructive lung disease (asthma), and it must include antiarthritic drugs and anticoagulant
drugs (blood thinners).  The program also covers diabetes and cardiac medications.  The
statute does not specify which drugs are covered and this allows the Bureau of Medical
Services to keep the program current as treatment changes, new drugs come on the
market and medical science progresses.  The Bureau determines which medications are
approved for each diagnosis covered by keeping current with the generally accepted
medical use, gleaned from review of the peer literature, current medical practice and the
federal Food and Drug Administration.  A listing of the covered medications as of
November 19,1997 is included in Appendix D.
Copayment.  A person holding a drug card issued under the Elderly Low-cost
Drug Program presents the card to the pharmacist at the time the prescription is filled.  If
the medication is prescribed for a covered diagnosis, the participant need pay only $2 or
20% of the usual price, whichever is greater, for the medication.  For some medications,
this is a significant savings to the participant.
Financing.  The Elderly Low-cost Drug Program is financed completely through
state funds.  Actual expenditures totaled $3,643,259 and $3,453,484 for Fiscal Years
1995-96 and 1996-97 respectively.  The program has been appropriated $3,994,328 and
$4,126,141 for Fiscal Years 1997-98 and 1998-99 respectively.  The Bureau of Medical
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Services’ administrative costs for this program are absorbed by the Medicaid program,
also run by the Bureau.
Drug Rebate Program.  The prescription drug program does not cover drugs
from manufactures that do not participate in the drug rebate program.  Under the rebate
program, the State enters into a contract with each individual drug manufacturer who
agrees to sell a particular drug in the State at the lowest cost the manufacturer sells the
drug to anyone.  This is the same arrangement that is used for the Medicaid program.  By
combining the Elderly Low-cost Drug Program with the Medicaid program in terms of
medication volume, the State is able to contract for a large quantity of medications at the
lowest possible price.
In simplified terms, the Elderly Low-cost Drug Program and the rebate program
work as follows:
· The consumer presents a prescription for a covered medication to the pharmacist,
along with the drug card.
· The pharmacist fills the prescription and collects the appropriate copayment amount.
· The pharmacist then bills the State for the difference between the agreed-upon selling
price for that medication (plus a dispensing fee) and the copayment actually collected.
· The State reimburses the pharmacy on a quarterly basis.
· The State then informs the manufacturer the amount of that medication prescribed and
filled under the program, and the manufacturer reimburses the State for the agreed
amount of the rebate.
The average savings for the State is about 19% due to the rebate program.  The
rebate funds received by the State are deposited back into the fund to pay for more
prescription drugs.  The result:  In Fiscal Year 1996-97, the State paid out $3,453,484 for
about $4,316,855 worth of drugs: the value of the rebate was over $833,000.  (These
figures do not factor in the copayment paid by program participants.)  The Bureau of
Medical Services has contracted with Goold Health Systems to process the pharmacist
claims and handle the reimbursement and rebate procedures.
Participation.  The Bureau of Medical Services estimates that there are currently
21,621 Maine residents who are eligible for the Elderly Low-cost Drug Program .  Maine
Revenue Services indicates that 13,671 cards were issued through November 26, 1997.
Only approximately 9,200 have used the card to date.  The size of this gap is at least partly
due to the fact that drug cards are issued automatically by the Maine Revenue Services to
eligible applicants for the Maine Residents Property Tax Program.  Another reason eligible
residents may not be using the program is that some people who have been issued cards
do not require medication covered by the program.  This may be because they require no
medication or because they are prescribed medication for illnesses other than those
covered by the program.  Another reason that card holders may not be using the program
is that some people have other prescription drug coverage, such as Medicaid or private
insurance.  The Elderly Low-cost Drug Program is the payor of last resort, meaning it will
pick up the cost of covered prescription drugs only if there is no other insurance coverage.
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B.  Other programs
1.  Medicaid.
Federal money funds roughly 2/3 of the Medicaid program in Maine, the
remainder coming from the General Fund and the hospital assessment tax.  The
total Medicaid expenditure in Maine for FY 97 was $1.1 billion.  The Medicaid
program consists of two main components, a “categorically needy” program and a
“medically needy” program.  The blind, the disabled, the elderly, pregnant women
and families with children are eligible under the categorically needy program.  To
qualify for Medicaid, these persons must have income (pegged to the federal
poverty level for a household of that size) and assets below a certain level.
(Appendix E contains federal poverty levels.)  A significant portion of the
Medicaid budget pays for prescription drugs, with a large part funding drugs for
the elderly, either institutionalized or at home.  Medicaid coverage is not limited to
specific diagnoses, and the copayment is very small.
2.  Medicare coverage
Medicare is available to an individual who is 65 or older, worked for at
least 10 years in Medicare-covered employment, and is a United States citizen or a
permanent resident.  Younger people may also qualify for coverage if they have a
disability or chronic kidney disease.  Medicare is divided into two parts:  Medicare
Part A (hospital insurance) and Medicare Part B (medical insurance).  Medicare
Part A is available to anyone 65 or older who qualifies for social security benefits.
It covers part of the costs of inpatient hospital care, limited care received in a
Medicare-certified skilled nursing facility, home health care and hospice care.  Part
B Medicare charges an individual a premium and has a deductible.  Among the
items it covers are doctor’s visits and laboratory tests, outpatient hospital services,
medical equipment, ambulance service, mammography services, and limited
coverage for dental surgery and services of a chiropractor, podiatrist and
optometrist.  Among the items not covered by Medicare are prescription drugs.
3.  Private insurance
Medicare recipients can choose to purchase private supplemental Medicare
insurance policies, known as “Medigap” policies, to provide them with additional
insurance coverage for medical services not covered by Medicare, including
prescription drugs.   As of June 1992, federal law mandates that all new Medigap
policies must match one of ten standardized benefit plans which are labeled A
through J.  Regardless of the insurance company the plan is purchased from, the
coverage each of the ten plan offers is identical from company to company.  Only
three of these Medigap policies offer a prescription drug benefit.  Plan J offers the
highest amount of prescription drug coverage.   This plan covers up to a total of
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$3,000 per year after a $250 deductible, and the premiums are up to $300 per
month.
Massachusetts is one of only three states that is not required to follow
Medigap guidelines.  Massachusetts had already standardized its Medigap
insurance before the federal legislation was enacted; as a result, the state was not
required to change its Medigap plans.  The Department of Professional and
Financial Regulation, Bureau of Insurance is reviewing the Massachusetts
experience with expanded Medigap prescription drug coverage.
4.  New York’s EPIC
Since 1977, eleven states have created pharmaceutical assistance progrms
to provide non-Medicaid low- and moderate-income elderly persons with financial
help in paying for prescription drugs.  These programs vary widely in their design
and costs.  There are also wide differences among state programs in the range of
medications covered, copayment amounts and income eligibility limits.
New York’s Elderly Pharmaceutical Insurance Coverage Program (EPIC)
was implemented in October of 1987.  The EPIC program establishes two separate
categories of participants.  Low cost comprehensive coverage is available for
elderly with lower incomes.  For the elderly with moderate incomes, catastrophic
coverage is available, but requires a higher premium or an annual deductible to
join.  The program enrollment fee is based on the income of the applicant.
Currently, New York State residents are eligible for EPIC if they are 65 or older,
with annual incomes up to $18,000 if single and $21,000 if married.  The
copayment charge ranges from $6 to $15 for each prescription, based on the
participant’s income. It was reported that in 1993, EPIC saved more in hospital
and nursing home costs than the State of New York spent on the program.  (EPIC
Evaluation Report to the Governor and Legislature: Maintaining Health, Dignity
and Independence, 1987-1995)
Although EPIC has been rated as successful by its participants, enrollment
in the program has been below projections since its start-up in 1987.  Several
barriers to program participation have been identified.  They include:  the
program’s complicated structure; a lack of understanding of the program’s
eligibility criteria and deductible requirements; and the program’s entry cost.  To
improve participation in the program, an extensive outreach effort was made to
enroll seniors in the program.  These efforts included mailers to seniors who had a
high probability of being eligible; explaining the program to seniors at community
events statewide; and establishing a toll-free hotline.  Other recommendations for
expanding program participation included periodic distribution of EPIC
information to seniors participating in other assistance programs and an increased
involvement of health care providers.
III Findings
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Members of the Task Force have identified the following inadequacies in the
existing Elderly low-cost Drug Program.
A.  Lack of public knowledge
The Bureau of Medical Services estimates that the number of residents of the State
eligible to participate in the program to be 21,621; the Maine Revenue Services has issued
13,671 cards through November 26, 1997, and only about 9,200 have used the card this
calendar year.  The Task Force believes that some eligible residents are simply unaware
that the program exists or that it may be of benefit to them.
B.  Serious illnesses and conditions not covered
The Task Force discussed the fact that although the diagnoses currently covered
by the program are chronic illnesses that require medication on a regular basis, there are
other serious illnesses that meet that description that are not covered.  One category of
prescription drugs that was mentioned several times are medications to treat high
cholesterol levels.  The Task Force also expressed concern that the organ transplant
population of Maine has few options for assistance in paying for necessary anti-rejection
medication.
C.  Age limitation
Some members of the Task Force believe that prescription drug coverage begins
too late.  By limiting eligibility to those 62 and older (the age threshold is 55 for those
who are disabled), the health of some older residents may have already deteriorated to the
point where they have ceased being productive members of the workforce.  By starting
coverage later than the onset of some health problems, the costs for treating those
conditions becomes much greater, and the persons are in worse health when they become
eligible for the program.
On the other hand, it was noted that generally there are more illnesses affecting
people at 65 than at 62, and covering more medications but at a higher threshold age may
help a broader category of people.
D.  Income limitations are too low
There was some discussion that the income limitations are too low, especially for
older residents who have one or more medical conditions that require medication on a
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regular basis.  As currently set, the income ceilings are around 130% of the federal
poverty guidelines for a family of one, and 120% for a family of two.
E.  Significant prescription drug costs may not be covered
Although the Task Force has no statistics to determine how many residents are
faced with this problem, there is concern that older persons with incomes above the
thresholds do not qualify, even if the amounts they pay for prescription drugs are so large
that their incomes, reduced by their medication costs, would bring them below the income
limitations.
F.  Leap frog income eligibility
A concern noted by the Maine Revenue Services and others is the problem of “leap
frog eligibility.”  The Elderly low-cost Drug Program includes an increased income
limitation for households that spend at least 40% of the household income on prescription
drugs that aren’t otherwise covered by insurance.  A resident who is eligible this year
because of the large outlay for prescription drugs last year may not qualify next year
because this year’s prescription drug costs consist of only the copayments.  Without a
drug card next year, the person’s prescription drug costs will again exceed 40% of the
household income, making the person eligible for the program the following year.
IV Recommendations
A.  Information from the Bureau of Medical Services
Because the members of the Task Force recognized that the success of
recommendations for improving access to the Elderly low-cost Drug Program would be
tied to the financial cost, the Task Force requested that the Bureau of Medical Services
provide information concerning the numbers of people affected and the projected costs
associated with modifying the Elderly low-cost Drug Program in different ways.  In
general, the Bureau was asked to provide information based on expanding the program by:
· Increasing the income limitations to higher percentages of the federal poverty
guidelines
 
· Lowering the minimum age to 60, 55 or 50
· Covering additional illnesses and conditions, specifically:
· HIV
· cholesterol
· osteoporosis
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· incontinence
· thyroid
· Parkinson’s Disease
· glaucoma
· Multiple Sclerosis
· Amyotrophic lateral sclerosis (ALS)
· Hodgkin’s disease
· cancer
· transplants
The Bureau performed a series of complicated calculations, based on several assumptions
and models of population and drug utilization.  The spreadsheets containing the results are
included as Appendix F.
B.  Recommendations
The Task Force’s recommendations are as follows.  The legislation implementing
the recommendations is included in Appendix G.
1.  Public education and outreach about the program
There should be improved public education about the Elderly Low Cost
Drug Program, and outreach efforts should be increased.  Specifically:
· Information should be included with the drug card when it is mailed to
the eligible recipient.  The Bureau of Medical Services should prepare
an easy to read brochure with telephone numbers and other sources for
more information about the program.  The Bureau should provide the
brochures to the Maine Revenue Services for inclusion in the mailings.
 
· The Bureau of Medical Services should develop posters explaining the
benefits of the program, who is eligible and how to take advantage of
the program.  These posters should be furnished to pharmacies, the
Area Agencies on Aging and other senior citizen service providers.
 
· The Bureau of Medical Services should develop flyers that are
appropriate for pharmacists to include in the bag along with the
customer’s prescription drug purchase.  The flyers should provide
information about the program, including how to apply for the benefits.
2.  Expand coverage through a Medicaid waiver
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The Department of Human Services should seek a waiver from the Health
Care Financing Authority to provide Medicaid prescription drug coverage for all
Maine residents who are 62 years of age or older and whose income is not more
than 185% of the federal poverty level.  The actual income limit should be flexible
as estimates dictate in order to approximate long term cost neutrality.  Cost
neutrality is based on the fact that access to prescription drugs for the elderly
decreases the need for institutionalization of those same people.  The decrease is
not immediate; a one- to two-year lead time is anticipated before the expenditures
for nursing home and other institutional care go down because improved health
due to the availability of prescription drugs.
The current estimate is that at the current federal Medicaid match rate, and
pursuant to a HCFA waiver, a prescription drug for the elderly program could
cover all residents 62 years of age and over whose income is not more than 185%
of the federal poverty level for an additional cost to the State of approximately
$7.3 million.  The estimates and calculations, in comparison to coverage for those
65 and over, are shown in the following chart.
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Drug Costs of Expanding the DEL Program to
Equal the Medicaid Drug Program
Age: 62 and + 65 and +
Federal Poverty Level: 185% 185%
Eligible/participating population
(assuming 75% utilization rate)
32,141 27,837
Capitated cost per person (aged,
noninstitutionalized rate)
$1,138 $1,138
Total capitated cost $36,576,458 $31,678,506
Less drug rebate
(about 18%)
($6,583,763) ($5.702,132)
Total costs $29,992,695 $25,976,374
State match (cost X 33.69%) $10,104,538 $8,751,440
Less current cost
    (includes deduction for
capitated disabled and age 55-
64 under DEL)
~$2,800,000 ~$2,800,000
-------------- --------------
NET COST
$7,304,538 $5,951,440
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These figures are based on preliminary estimates.  The final Task Force
recommendation may change slightly to take advantage of more accurate
population and cost figures as the Bureau refines its estimates and projections.
The Task Force acknowledges inflation in the costs of drugs, and that new,
more expensive and more complex drugs are developed and come on the market at
a regular pace.  This will increase the money spent on prescription drugs on a
regular basis.  By the same token however, nursing home costs will continue to
increase, and illnesses that give patients no option but to become nursing home
residents today may be treated with new drugs tomorrow that will keep them
healthier and allow them to stay in their own homes.  The cost of the new therapies
will still be less than the costs of institutionalizing our older population.  The
Bureau of Medical Services estimated that it spent $203 million in 1997 for
nursing home care.
Even more important than the financial aspects is the improved quality of
life that access to prescription drugs can provide Maine’s elderly.  Helping older
residents stay healthier and productive participants in the community results in
benefits shared by all.
The Task Force requests that the Bureau of Medical Services report to the
Joint Standing Committee on Health and Human Services regularly between now
and the end of the Second Regular Session of the 118th Legislature regarding the
progress of the Medicaid waiver application.  The Task Force supports
adjustments to the 185% goal as necessary.
3.  Interim expansion
Because the Medicaid waiver process is lengthy, the Task Force
recommends that the Low-cost Drugs for the Elderly Program be expanded in the
interim.  The Task Force supports expansion based on the same General Fund
obligation that will be necessary for the Medicaid waiver recommended above.
Although the members do not have strong feelings as to whether the program
should be expanded by increasing the income limits or by covering more
medications or both, the members made a recommendation at the Task Force’s last
meeting for increasing the income limits to 185% of the federal poverty level   This
recommendation is subject to change based on the additional figures the Bureau of
Medical Services is able to provide.  Preliminary calculations estimate that the
entire new $7.3 million would be necessary to cover that additional population.
That amount of increased funding would not cover additional drugs, or a lower
age threshold.  Draft legislation carrying out this recommendation is included in
Appendix G.  It should be noted that the Task Force may support a different mix
of expansion should the Bureau’s figures indicate that the benefits would be
greater if the income limit were raised to only 150% but additional categories of
medication were covered.  At this point, the Task Force expresses no preference
for which medications should be covered under the expanded program.
4.  Insurance issues
The Task Force became aware in the process of exploring access to
prescription drugs for the elderly that there is a serious problem for organ
transplant patients and their families in affording the life-sustaining anti-rejection
drugs that are required for the rest of the transplant patient’s life.  Once transplant
patients reach the age of 65 and rely on Medicare benefits, their anti-rejection
drugs are not covered.  The Task Force recommends that both the Joint Standing
Committee on Banking and Insurance and the Joint Standing Committee on Health
and Human Services investigate the problem of unavailability of affordable
insurance coverage for transplant patients’ prescription drugs.  One specific area
that the Task Force suggests the two committees examine is the impact of Public
Law 1997, chapter 370 on this issue.  This law was passed during the 117th
Legislature, First Special Session; it enacted a new provision in the Community
Rating Law that allows insurance companies to set a separate community rate for
guaranteed renewable individual policies of Medicare eligible recipients.  The Task
Force recommends that the Bureau of Insurance continue to research the issue
and, in conjunction with the two committees, develop a method of addressing the
problem.  A copy of the letters to the committees and the Bureau are contained in
Appendix H.
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CHAPTER 560
H.P. 1357 - L.D. 1904
An Act to Discourage Smoking, Provide Tax Relief and Improve
the Health of Maine Citizens
Be it enacted by the People of the State of Maine as follows:
. . .
PART E
Sec. E-1. Task Force on Improving Access to Prescription Drugs for the
Elderly established.  The Task Force on Improving Access to Prescription Drugs for the
Elderly, referred to in this Part as the "task force," is established.
Sec. E-2. Membership.  The task force consists of 9 members appointed as
follows:
1.  Three members, appointed by the President of the Senate;
2.  Three members, appointed by the Speaker of the House of Representatives; and
3.  Three members, appointed by the Governor.
The chair of the task force must be selected jointly from the members by the
President of the Senate, the Speaker of the House of Representatives and the Governor.
Sec. E-3. Appointments.  All appointments must be made no later than 30 days
following the effective date of this Part.  The appointing authorities shall notify the
Executive Director of the Legislative Council upon making their appointments.  When the
appointment of all members is complete, the Executive Director of the Legislative Council
shall call and convene the first meeting of the task force no later than October 10, 1997.
Sec. E-4.  Duties.  The task force shall determine and recommend methods on
improving access to prescription drugs for the State's elderly citizens.
Sec. E-5.  Staff assistance.  The task force may request staffing and clerical
assistance from the Legislative Council.
Sec. E-6.  Compensation.  Members of the task force who are Legislators are
entitled to receive the legislative per diem, as defined in the Maine Revised Statutes, Title
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3, section 2, and reimbursement for travel and other necessary expenses for each day's
attendance at meetings of the task force.  Other members of the task force are not entitled
to compensation or reimbursement for expenses.
Sec. E-7.  Report.  The task force shall submit its recommendations, with any
necessary implementing legislation, to the Governor and the Legislature  by January 15,
1998.  The Joint Standing Committee on Health and Human Services may report out
legislation based on the report of the task force.
Sec. E-8.  Appropriation.  The following funds are appropriated from the General
Fund to carry out the purposes of this Part.
1997-98
LEGISLATURE
Task Force on Improving Access
to Prescription Drugs for the
Elderly
Personal Services $1,320
All Other   1,700
Provides funds for the per diem and
expenses of legislative members and
for miscellaneous costs, including
printing of the Task Force on
Improving Access to Prescription
Drugs for the Elderly.
LEGISLATURE ______
TOTAL $3,020
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TASK FORCE ON IMPROVING ACCESS TO PRESCRIPTION DRUGS FOR
THE ELDERLY
(Chapter 560, P.L. 1997, Part E)
Membership
Appointments by the Governor
Robert Philbrook
295 Capisic Street
Portland, Maine  04102
Tel:  772-5636
Jean Deyoe
Box 29
Corea, Maine  04624
Tel:  963-7022
John H. Grotton
14 Dresser Road
Scarborough, ME  04074
Tel.  883-9064
Appointments by the President
John Marvin
15 Fuller Road
Augusta, Maine  04330
Tel:  623-3300
Sen. Chellie Pingree, Chair
92 Mills Street
North Haven, Maine  04853
Tel:  867-0966
Roger Hare
High Point Terrace
West Buxton, Maine  04093
Tel:  727-3026
Appointments by the Speaker
Rep. Joseph Jabar
One Center Street
Waterville, Maine  04901
Tel:  872-2357
Rep. Joseph Brooks
2 Goshen Road
Winterport, Maine  04496
Tel:  223-5041
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Rep. Robert Cameron
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Office of Policy and Legal Analysis
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13 State House Station
Augusta, Maine 04333
Tel:  287-1670    FAX:  287-1275
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TITLE 22
SUBTITLE 2
HEALTH
PART 1
ADMINISTRATION
CHAPTER 101
GENERAL PROVISIONS
22 § 254. Elderly low-cost drug program
The Department of Human Services may conduct a program to provide low-cost
prescription and nonprescription drugs, medication and medical supplies to disadvantaged,
elderly individuals.  In any year in which this program is conducted, it must include any
prescription drugs used for the treatment of chronic obstructive lung disease.
In any year in which this program is conducted, it must include antiarthritic drugs.
In any year in which this program is conducted, it must include anticoagulant
drugs.
The commissioner shall provide for sufficient personnel to ensure efficient
administration of the program.  The extent and the magnitude of the program shall be
determined by the commissioner on the basis of the calculated need of the recipient
population and the available funds.  The department may not spend more on this program
than is available through appropriations from the General Fund, dedicated revenue, federal
or other grants and other established and committed funding sources.  The commissioner
may accept, for the purposes of carrying out this program, federal funds appropriated
under any federal law relating to the furnishing of free or low-cost drugs to disadvantaged,
elderly individuals and may take such action as is necessary for the purposes of carrying
out that federal law and may accept from any other agency of government, individual,
group or corporation such funds as may be available to carry out this chapter.
The commissioner may adopt rules relating to the conduct of this program.  These
rules shall be promulgated in accordance with the Maine Administrative Procedure Act,
Title 5, chapter 375, and shall be related to the following aspects of this program:
1.  Prescription and nonprescription drugs.  The kinds of prescription and
nonprescription drugs, medications and medical supplies which may be made available
through the operation of this program;
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2.  Individuals eligible for participation.  Eligibility status of individuals shall be
determined by the State Tax Assessor pursuant to Title 36, chapter 905;
3.  Specifications for administration of program.  Specifications for the
administration and management of the program which may include, but not be limited to,
program objectives, accounting and handling practices, supervisory authority and
evaluation methodology;
4.  Method of prescribing or ordering drugs.  The method of prescribing or
ordering these drugs, which may include, but is not limited to, the use of standard or
larger prescription refill sizes so as to minimize operational costs and to maximize
economy.  Unless the prescribing physician indicates otherwise, the use of generic or
chemically equivalent drugs is required, provided that these drugs are of the same quality
and have the same mode of delivery as is provided to the general public, consistent with
good pharmaceutical practice.  Each prescription filled must be for a supply of 90 days
unless the prescribing physician or the recipient requests otherwise;
4-A.  Payment for drugs provided.  The commissioner may establish the amount
of payment to be made by recipients toward the cost of prescription or nonprescription
drugs, medication and medical supplies furnished under this program provided that the
total cost for any covered purchase of a prescription or nonprescription drug or
medication does not exceed  20% of the price allowed for that prescription under program
rules or $2, whichever is greater.  If a recipient is prescribed a drug in a quantity
specifically intended by the provider or pharmacist, for the recipient's health and welfare,
to last less than one month, only one payment for that drug for that month is required;
4-B.  Limitation.   (repealed)
5.  Other rules.  Such other rules as may be necessary to efficiently and effectively
manage and operate a program within the intent of this section.
6.  Establish a planned program.  (repealed)
7.  Wholesale price.  Wholesale price means the average price paid by a
wholesaler to a pharmaceutical manufacturer for a product distributed for retail sale.
Wholesale price includes a deduction for any customary prompt payment discounts.
8.  Drug rebate program.  Effective May 1, 1992, payment must be denied for
drugs from manufacturers that do not enter into a rebate agreement with the department
for prescription drugs included in the list of approved drugs under this program.   Each
agreement must provide that the pharmaceutical manufacturer make rebate payments to
the department according to the following schedule.
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A.  For the period beginning May 1, 1992 and ending September 30, 1992, the
rebate percentage is equal to 11% of the manufacturer's wholesale price for the
total number of dosage units of each form and strength of a prescription drug that
the department reports as reimbursed to providers of prescription drugs, provided
payments are not due until 30 days following the manufacturer's receipt of
utilization data supplied by the department, including the number of dosage units
reimbursed to providers of prescription drugs during the period for which payment
is due.
B.  For the quarters beginning October 1, 1992, the rebate percentage is equal to
the percentage recommended by the federal Health Care Financing Administration
of the manufacturer's wholesale price for the total number of dosage units of each
form and strength of a prescription drug that the department reports as reimbursed
to providers of prescription drugs, provided payments are not due until 30 days
following the manufacturer's receipt of utilization data supplied by the department,
including the number of dosage units reimbursed to providers of prescriptions
drugs during the period for which payments is due.
Upon receipt of data from the department, the pharmaceutical manufacturer shall calculate
the quarterly payment.  If a discrepancy is discovered, the department may, at its expense,
hire a mutually agreed-upon independent auditor to verify the pharmaceutical
manufacturer's calculation.  If a discrepancy is still found, the pharmaceutical manufacturer
shall justify its calculation or make payment to the department for any additional amount
due.  The pharmaceutical manufacturer may, at its expense, hire a mutually agreed-upon
independent auditor to verify the accuracy of the utilization data provided by the
department.  If a discrepancy is discovered, the department shall justify its data or refund
any excess payment to the pharmaceutical manufacturer.
If the dispute over the rebate amount is not resolved, a request for a hearing with
supporting documentation must be submitted to the Administrative Hearings Unit.  Failure
to resolve the dispute may be cause for terminating the drug rebate agreement and denying
payment to the pharmaceutical manufacturer for any drugs.
All prescription drugs of a pharmaceutical manufacturer who enters into an agreement
pursuant to this subsection that appear on the approved list of drugs must be immediately
available and the cost of the drugs must be reimbursed and is not subject to any
restrictions or prior authorization requirements.  Any prescription drug of a manufacturer
that does not enter into an agreement is not reimbursable unless the department
determines the prescription drug is essential.  The department shall seek a manufacturer's
rebate for pharmaceuticals used in the Maine Health Program.
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TITLE 36
CHAPTER 905
CERTIFICATION OF ELIGIBILITY FOR ELDERLY LOW
COST DRUG PROGRAM
36 § 6161. Purpose
The purpose of this chapter is to determine and certify the eligibility status of
individuals for the elderly low cost drug program.
36 § 6162. Eligibility criteria; appeal             (REPEALED)
36 § 6162-A. Eligibility; definitions; appeal
Individuals are eligible for this program if they meet the following conditions.
1.  Age.  Individuals qualify under this program if they meet the age requirements
for an elderly household under chapter 901 and its successors.
2.  Income.  Eligibility for this program is determined by the same income levels as
eligibility for elderly households is determined under chapter 907, except that individuals
are also eligible for this program if the household spends at least 40% of its income on
unreimbursed direct medical expenses for prescription drugs and the household income is
not more than 25% higher than the levels specified in chapter 907.
3.  Residence.  An individual must be a legal resident of this State at the time the
application is filed.
4.  Limitation.  An individual does not qualify under this program if receiving
state supplemental income benefits.
5.  Definitions.  As used in this chapter, unless the context clearly indicates
otherwise, all terms have the same meaning as in chapter 901 and its successors.
6.  Adjustment.  The income limitations provided in this section shall be adjusted
annually in the same manner as provided in chapter 901 and its successors.
7.  Appeals.  The eligibility decision, made by the State Tax Assessor or his
designee, shall be final, subject to appeal in accordance with the Maine Administrative
Procedure Act, Title 5, chapter 375.
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36 § 6163. Administration
The State Tax Assessor shall make available suitable applications with instructions
for applicants. The State Tax Assessor shall accept applications for eligibility throughout
the year and no application may be denied on the basis that it was not submitted before a
deadline set by the State Tax Assessor.
36 § 6164. Certification
The State Tax Assessor shall annually issue an identification certificate to eligible
applicants. The certificate shall be valid for the 15-month period beginning October 1st of
the current calendar year through December 31st of the following year.
CHAPTER 901
THE ELDERLY HOUSEHOLDERS TAX AND RENT REFUND
ACT
(repealed  PL 1987, c. 516)
(replaced by Chapter 907)
CHAPTER 907
MAINE RESIDENTS PROPERTY TAX PROGRAM
36 § 6201. Definitions
As used in this chapter, unless the context otherwise indicates, the following terms
have the following meanings.
1.  Benefit base.  "Benefit base" means property taxes accrued or rent constituting
property taxes accrued.  In the case of a claimant paying both rent and property taxes for a
homestead, benefit base means both property taxes accrued and rent constituting property
taxes accrued.
2.  Claimant.  "Claimant" means an individual who has filed a claim under this
chapter and was domiciled in this State and occupied a homestead in this State during the
entire calendar year preceding the year in which claim for relief under this chapter is filed.
Regardless of how many names of individuals appear on the property deed, the person
who meets the qualifications described in this subsection and proves sole responsibility for
the payment of the property taxes on the subject property is the claimant for that property.
If 2 or more individuals meet the qualifications in this subsection and share the payment of
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the rent or the responsibility for the payment of the property taxes, each individual may
apply on the basis of the rent paid or the property taxes levied on the homestead that
reflect the ownership percentage of the claimant and the claimant's household.
If 2 or more individuals claim the same property, the matter must be referred to the State
Tax Assessor whose decision is final.  Ownership of a homestead under this chapter may
be by fee, by life tenancy, by bond for deed, as mortgagee or any other possessory interest
in which the owner is personally responsible for the tax for which a refund is claimed.
3.  Elderly household. "Elderly household" means a household in which:
A.  At least one member of the household has attained the age of 62 during the
year for which relief is requested;
B.  The claimant is currently not married and has attained the age of 55 during the
year for which relief is requested and is, due to disability, receiving federal
disability payments, such as supplemental security income; or
C.  The claimant is currently married and has attained the age of 55 during the year
for which relief is requested and both the claimant and the claimant's spouse are,
due to disability, receiving federal disability payments, such as supplemental
security income.
4.  Gross rent. "Gross rent" means rental paid at arm's length solely for the right
of occupancy of a homestead, exclusive of charges for any utilities, services, furniture,
furnishings or personal property appliances furnished by the landlord as part of the rental
agreement, whether or not expressly set out in the rental agreement. If the landlord and
tenant have not dealt with each other at arm's length, and the State Tax Assessor is
satisfied that the gross rent charged was excessive, the State Tax Assessor may adjust the
gross rent to a reasonable amount for purposes of this chapter.
5.  Homestead.  "Homestead" means the dwelling owned or rented by the claimant
or held in a revocable living trust for the benefit of the claimant and occupied by the
claimant and the claimant's dependents as a home, and may consist of a part of a
multidwelling or multipurpose building and a part of the land, up to 10 acres, upon which
it is built. "Owned" includes a vendee in possession under a land contract and of one or
more joint tenants or tenants in common.
6.  Household. "Household" means a claimant and spouse and members of the
household for whom the claimant under this chapter is entitled to claim an exemption as a
dependent under Part 8 for the year for which relief is requested.
7.  Household income. "Household income" means all income received by all
persons of a household in a calendar year while members of the household.
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8.  Household income eligibility adjustment factor. "Household income
eligibility adjustment factor" means one plus the annualized cost-of-living adjustments for
Social Security retirement benefits during the year for which relief is requested.
9.  Income. "Income" means the sum of Maine adjusted gross income determined
in accordance with Part 8, the amount of capital gains excluded from adjusted gross
income, the absolute value of the amount of trade or business loss, net operating loss
carry-over, capital loss, rental loss, farm loss, partnership or S Corporation loss included
in adjusted gross income, alimony, inheritance, life insurance proceeds paid on death of
insured, nontaxable lawsuit rewards, such as slander, libel and pain and suffering,
excluding reimbursements such as medical and legal expenses associated with the case,
support money, nontaxable strike benefits, the gross amount of any pension or annuity,
including railroad retirement benefits, all payments received under the federal Social
Security Act, state unemployment insurance laws, veterans' disability pensions, nontaxable
interest received from the Federal Government or any of its instrumentalities, interest or
dividends on obligations or securities of this State and its political subdivisions and
authorities, workers' compensation and the gross amount of "loss of time" insurance, cash
public assistance and relief, but not including relief granted under this chapter. Income
does not include the first $5,000 in the proceeds from a life insurance policy, whether paid
in a lump sum or in the form of an annuity.  Income also does not include gifts from
nongovernmental sources or surplus foods or other relief in kind supplied by a
governmental agency.
10.  Property taxes accrued. "Property taxes accrued" means property taxes
exclusive of special assessment, delinquent interest and charges for service levied on a
claimant's homestead in this State as of April 1, 1972, or any tax year thereafter. If a
homestead is owned by 2 or more persons or entities as joint tenants or tenants in
common, and one or more persons or entities are not members of the claimant's
household, "property taxes accrued" is that part of property taxes levied on the homestead
that reflects the ownership percentage of the claimant and the claimant's household. If a
claimant and spouse own their homestead for part of the year for which relief is requested
and rent it or a different homestead for part of the same tax year, "property taxes accrued"
means taxes levied on the homestead on April 1st, multiplied by the percentage of 12
months that the property was owned and occupied by the household as its homestead
during the year for which relief is requested. When a household owns and occupies 2 or
more different homesteads in this State in the same tax year, property taxes accrued relate
only to that property occupied by the household as a homestead on April 1st. If a
homestead is an integral part of a larger unit such as a farm, or a multipurpose or
multidwelling building, property taxes accrued are that percentage of the total property
taxes accrued that the value of the homestead is of the total value, except that property
taxes accrued do not include any portion of taxes claimed as a business expense for federal
income tax purposes. For purposes of this chapter, "unit" refers to the parcel of property
separately assessed of which the homestead is a part.
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11.  Rent constituting property taxes accrued for an elderly household.  "Rent
constituting property taxes accrued for an elderly household" means 25% of the gross rent
actually paid in cash or its equivalent in any tax year by a claimant and the claimant's
household solely for the right of occupancy of their Maine homestead in the tax year and
which rent constitutes the basis, in the succeeding calendar year, of a claim for relief under
this chapter by the claimant.
11-A.  Rent constituting property taxes accrued for nonelderly household.
"Rent constituting property taxes accrued for nonelderly household" means 15% of the
gross rent actually paid in cash or its equivalent in any tax year by a claimant and the
claimant's household solely for the right of occupancy of their Maine homestead in the tax
year and which rent constitutes the basis, in the succeeding calendar year, of a claim for
relief under this chapter by the claimant.
12.  Year for which relief is requested. "Year for which relief is requested"
means the calendar year preceding that in which the claim is filed.  For a claim filed in
January of any year, "year for which relief is requested" means the calendar year 2 years
preceding that in which the claim is filed.
36 § 6201-A. Short title
This chapter shall be known and may be cited as the "Maine Residents Property
Tax Program."
36 § 6202. Claim is personal
The right to file a claim under this chapter is personal to the claimant and does not
survive the claimant's death, but the right may be exercised on behalf of a claimant by the
claimant's legal guardian or attorney-in-fact. If a claimant dies after having filed a timely
claim, the amount thereof must be disbursed to another member of the household as
determined by the State Tax Assessor.
If the claimant was the only member of a household, the claim may be paid to the
claimant's personal representative, but if one is not appointed within 2 years of the filing of
the claim, the amount of the claim escheats to the State.
36 § 6203. Claim to be paid from General Fund
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The amount of the claim after certification by the State Tax Assessor may be paid
to claimant from the General Fund. No interest may be allowed on any payment made to a
claimant pursuant to this chapter.
36 § 6204. Filing date
A claim may not be paid unless the claim is filed with the Bureau of Revenue
Services on or after August 1st and on or before the following January 31st.
36 § 6205. One claim per household
Only one claimant per household or homestead per year shall be entitled to relief
under this chapter.
36 § 6206. Income limitations for elderly households
A claimant representing an elderly household shall qualify for the following
benefits subject to the following income limitations.
1.  Single-member elderly households. For single-member elderly households,
the benefit shall be calculated as follows:
If household income equals:The benefit equals:
$    0 to $6,800 100% of the benefit base up to a maximum of $400
$6,801 to $7,000 75% of the benefit base up to a maximum of $300
$7,001 to $7,200 50% of the benefit base up to a maximum of $200
$7,201 to $7,400 25% of the benefit base up to a maximum of $100
2.  Elderly households with 2 or more members. For elderly households with 2
or more members, the benefit shall be calculated as follows:
If household income equals:The benefit equals:
$    0 to $8,100 100% of the benefit base up to a maximum of $400
$8,101 to $8,500 75% of the benefit base up to a maximum of $300
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$8,501 to $8,800 50% of the benefit base up to a maximum of $200
$8,801 to $9,200 25% of the benefit base up to a maximum of $100
3.  Minimum benefit. No claim of less than $5 may be granted.
36 § 6207. Income limitations for nonelderly  households
A claimant representing a nonelderly household qualifies for the following benefits
subject to the following income limitations.
1.  Benefit calculation.  For claimants representing a nonelderly household, the
benefit is calculated as follows:
A.
A-1.  Fifty percent of that portion of the benefit base that exceeds 4% but does not
exceed 8% of income plus 100% of that portion of the benefit base that exceeds
8% of income to a maximum payment of $1,000.
2.  Income eligibility.  Single-member households with household incomes in
excess of $25,700 and households with 2 or more members with a household income in
excess of $40,000 are not eligible for a benefit.
A.
3.  Subsidized housing; special needs payment.  A claim may not be granted
under this section to claimants:
A.  Whose housing costs for the year for which relief is requested were subsidized
by government programs that limit housing costs to a percentage of household
income.
B.  Who are receiving temporary assistance for needy families under Title 22,
chapter 1053-B and are eligible for the housing special needs payment pursuant to
Title 22, section 3762, subsection 3, paragraph B, subparagraph (6).
4. Minimum benefit.  A claim of less than $10 may not be granted.
36 § 6208. Elderly option
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If a claimant representing an elderly household would qualify for a larger benefit
under section 6207 than he would receive under section 6206, then that claimant may
choose to receive the benefit calculated under section 6207.
36 § 6209. Annual adjustment
1.  Household limitation adjustment.  Beginning March 1, 1989, and annually
thereafter, the State Tax Assessor shall determine the household income eligibility
adjustment factor. That factor shall be multiplied by the income limitations in section
6206, applicable for the year prior to that for which relief is requested. The result shall be
rounded to the nearest $100 and shall apply to the year for which relief is requested
corresponding to the year on which the annualized cost of living adjustments were based.
Beginning March 1, 1991, the same procedure shall be employed to adjust the income
limitation in section 6207, subsection 2.
36 § 6210. Administration
The State Tax Assessor shall make available suitable forms with instructions for
claimants. The claim shall be in the form the State Tax Assessor may prescribe and shall be
signed by the claimant.
The State Tax Assessor shall include a checkoff to request an application for the
Maine Residents Property Tax Program on the individual income tax form.  The assessor
shall also provide for the option of filing an application for the Maine Residents Property
Tax Program using the telefile system established by the assessor.
36 § 6211. Audit of claim
If, on the audit of any claim filed under this chapter, the State Tax Assessor
determines the amount to have been incorrectly determined, he shall redetermine the claim
and notify the claimant of the redetermination and his reasons for it. The redetermination
shall be final unless appealed to the State Tax Assessor within 30 days of notice.
36 § 6212. Denial of claim
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If it is determined that a claim is excessive and was filed with fraudulent intent, the
claim shall be disallowed in full and, if the claim has been paid the amount paid may be
recovered by assessment, and the assessment shall bear interest from the date of payment
or credit of the claim, until refunded or paid, at the rate of 1% per month. The claimant in
such case, and any person who assisted in the preparation or filing of such excessive claim
or supplied information upon which such excessive claim was prepared, with fraudulent
intent, commits a Class E crime. If it is determined that a claim is excessive and was
negligently prepared, 10% of the corrected claim shall be disallowed, and if the claim has
been paid the proper portion of any amount paid shall be similarly recovered by
assessment, and the assessment shall bear interest at 1% per month from the date of
payment until refunded.  Any claimant or spouse with an unpaid liability arising from this
section is disqualified from benefits under this chapter.
36 § 6213. Appeal
A denial in whole or in part of relief claimed under this chapter may be appealed in
accordance with section 151 and the Maine Administrative Procedure Act.
36 § 6214. Disallowance of certain claims
A claim shall be disallowed, if the State Tax Assessor finds that the claimant
received title to his homestead primarily for the purpose of receiving benefits under this
chapter.
36 § 6215. Extension of time for filing claims
In case of sickness, absence or other disability, or if, in his judgment, good cause
exists, the State Tax Assessor may extend, for a period not to exceed 6 months, the time
for filing a claim.
36 § 6216. Protection from loss of benefits
It is the intent of the Legislature that any claim paid under this chapter shall
supplement any benefits paid under aid to the aged, blind and disabled or any program
which succeeds or supplants it. The Department of Human Services shall take any such
action as may be necessary to assure that recipients of aid to the aged, blind and disabled
shall continue to receive as high a percentage of their current assistance as may be
possible. To carry out this legislative directive, the department shall utilize all the state
funds expected to be saved by a reduction in benefits of recipients of aid to the aged, blind
and disabled resulting from this chapter to raise the standards of aid to the aged, blind and
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disabled at a total cost in state funds equivalent to the savings in state funds which would
be expected as a result of this chapter.
Benefits received under this chapter may not be included as income for purposes of
any state or municipally administered public benefit program but may be considered for
purposes of determining eligibility for abatement under section 841, subsection 2.
These benefits do not duplicate and shall not reduce the amount of any individual's
payment under the Temporary Assistance for Needy Families program because those
payments are insufficient to meet the total amount of money determined to be needed for
housing in accordance with the state standard of need under that program.
36 § 6217. Sunset           (REPEALED)
36 § 6218. Readability; application; instructions
The application form and instructions used by applicants for assistance under the
Maine Residents Property Tax Program and its successor, if any, shall have a readability
score, as determined by a recognized instrument for measuring adult literacy levels,
equivalent to no higher than a 6th grade reading level.
36 § 6219. Outreach plan required
The Bureau of Revenue Services shall develop and implement a plan of outreach
to ensure that all eligible households are made aware of assistance available under the
Maine Residents Property Tax Program and its successor, if any.
36 § 6220. Coordination required
The Bureau of Revenue Services shall seek the advice and cooperation of the
Bureau of Elder and Adult Services; the Bureau of Family Indpendence; the Bureau of
Child and Family Services; advocates for elderly and low-income individuals; the Maine
Literacy Coalition; and other interested agencies and organizations in developing the
application form and instruction booklet for the Maine Residents Property Tax Program
and the outreach plan required by section 6219.
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APPENDIX 1
MAINE DRUGS FOR THE ELDERLY PROGRAM
HEART - HYPERTENSION - DIABETIC DRUGS
CO-PAY $3.00 SINGLE SOURCE BRAND, GENERIC
$5.00 MULTI-SOURCE BRAND
GENERIC NAME COMMON KNOWN BRAND NAME(S)
HEART - HYPERTENSION - DIABETIC DRUGS
ACEBUTOLOL HYDROCHLORIDE SECTRAL
ACETAZOLAMIDE DIAMOX
ACETOHEXAMIDE DYMELOR
ACETYLDIGITOXIN ACYLANID
ALSEROXYLON RAUWILOID
AMILORIDE HCL & HYDROCHLOROTHIAZIDE, MSD MODURETIC
AMMONIUM CHLORIDE TWIN-K
ATENOLOL TENORMIN
ATENOLAL & CHLORTHALIDONE TENORETIC
BENDROFLUMETHIAZIDE & RAUWOLFIA RAUZIDE
SERPENTINA
BENZTHIAZIDE AQUATAG, EXNA
BENZTHIAZIDE & RESERPINE EXNA-R
BUMETANIDE BUMEX
BUTABARBITAL HYDROCHLOROTHIAZIDE BUTISERPAZIDE
& RESERPINE
BUTABARBITAL SODIUM & RESERPINE BUTISERPINE
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CAPTOPRIL CAPOTEN
CAPTOPRIL & HYDROCHLOROTHIAZIDE CAPOCIDE
CHLORMERODRIN NEOHYDRIN
CHLOROTHIAZIDE DIURIL, DIURIGEN
CHLOROTHIAZIDE & RESERPINE DIUPRES, THIASERP
CHLORPROPAMIDE DIABINESE
CHLORTHALIDONE HYGROTON
CHLORTHALIDONE W/RESERPINE REGROTON, DEMI-REGROTON
CHLORTHALIDONE & CLONIDINE HYDROCHLORIDE COMBIPRES
CLONIDINE HYDROCHLORIDE CATAPRES
CRYPTENAMINE UNITENSEN
CYCLOTHIAZIDE ANHYDRON
DESERPIDINE HARMONYL
DESLANOSIDE CEDILANID-D
DIAZOXIDE PROGLYCEM
DICHLORPHENAMIDE DARANIDE
DIGITALIS PIL DIGIS, DIGIFORTIS
DIGITOXIN CRYSTODIGIN. PURODIGIN
DIGOXIN LANOXIN
DIHYDROERGATAMINE MESYLATE EMBOLEX
& HEPARIN SODIUM
DILITIAZEM HCL CARDIZEM
DISOPYRAMIDE PHOSPHATE NORPACE
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ENALAPRIL MALEATE, MSD VASOTEC
ETHACRYNATE SOCIUM, MSD EDECRIN
ERYTHRITYL TETRANITRATE CARDILATE
ETHOXZOLAMIDE ETHAMIDE
FUROSEMIDE LASIX
GITALIN GITALIGIN
GLIPIZIDE GLUCOTROL
GLUCAGON GLUCAGON
GLYBURIDE DIABETA, MICRONASE
GUANABENZ ACETATE WYTENSIN
GUANADREL SULFATE HYLOREL
GUANETHIDINE SULFATE ISMELIN
GUANFACIDE HCL TENEX
HYDRALAZINE HCL APRESOLINE
HYDRALAZINE HYDROCHLORIDE & HYDRO- APRESAZIDE,
CHLOROTHIAZIDE APRESOLINE, ESIDREX
HYDROCHLOROTHIAZIDE ESIDRIX, LOQUA,
THIURETIC
HYDROCHLOROTHIAZIDE & DESERPIDINE ORETICYL
HYDROCHLOROTHIAZrDE ESIMIL
& GUANETHIDINE SULFATE
HYDROCHLOROTHIAZIDE, HHR, HRH, SER-AP-ES
HYDRALIZINE HYDROCHLORIDE & RESERPINE
HYDROCHLOROTHIAZIDE HYDROMAL
HYDROCHLOROTHIAZIDE & RESERPINE AQUASERP,
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HYDROSERPIN
HYDROFLUMETHIAZIDE DIUCARDIN, SALURON
HYDROFLUMETHIAZIDE & RESERPINE SALUTENSIN
INDAPAMIDE LOZOL
INSULIN ALL BRANDS
ISMITROL INVENEX MANNITOL
ISOSORBIDE DINITRATE ISORDIL, SORBITRATE
LABETALOL HYDROCHLORIDE TRANDATE, 
NORMODYNE
LIDOCAINE HCL XYLOCAINE IV
LISENOPRIL ZESTRIL
MANNITOL HEXANITRATE NITRANITOL
MANNITOL HEXANITRATE & PHENOBARBITAL NITRANITOL W/PB
MECAMYLAMINE HYDROCHLORIDE INVERSINE
MERCAPTOMERIN SODIUM THIOMERIN
METHAZ0LAMIDE NEPTAZANE
METHYCLOTHIAZIDE AQUATENSEN, ENDURON
METHYCLOTHIAZIDE & DESERPIDINE ENDURONYL, ENDURONYL
FORTE
METHYLDOPA ALDOMET
METHYLDOPA-CHLORTHIAZIDE ALDOCLOR
METHYLDOPA-HYDROCHLOROTHIAZIDE ALDORIL
METOLAZONE DIULO
METOLAZONE ZAROXOLYN
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METOPROLOL TARTRATE LOPRESSOR
METOPROLOL TARTRATE LOPRESSOR HCT
& HYDROCHLOROTHIAZIDE
MINOXIDIL LONITEN
NADOLOL CORGARD
NADOLOL & BENDROFLUMETHIAZIDE CORZIDE
NIFEDIPINE PROCARDIA, ADALAT
NITROGLYCERIN NITRO DISC, TRANSDERM
NITRO, PROGINA
PARAGYLINE HYDROCHLORIDE EUTONYL
PARAGYLINE HYDROCHLORIDE EUTRON
& METHYCLOTHIAZIDE
PAPAYERINE HCL CERESPAN, DURABID, 
PAVA, MEAD, PAVABID
PAPAVERINE HCL & PHENOBARBITAL PAVABID/PB
PENTOIFYLLINE TRENTAL
PHENFORMIN HYDROCHLORIDE MELTROL, DBI, DBI-TD
PHENTOLAMINE REGITINE
PINDOLOL VISKEN
POLYTHIAZIDE RENESE
POLYTHIAZIDE & RESERPINE RENESE-R
PRAZOSIN HYDROCHLORIDE MINIPRESS
PRAZOSIN HYDROCHLORIDE & POLYTHIAZIDE MINIZIDE
PROCAINAMIDE HYDROCHLORIDE PROCAMIDE, 
PRONESTYL, PROCAN
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PROPRANOLOL HYDROCHLORIDE INDERAL
PROPRANOLOL HYDROCHLORIDE & HYDRO- INDERIDE
CHLORATHIAZIDE
QUINETHAZONE HYDROMOX
QUINIDINE GLUCONATE QUINAGLUTE,
DURAQUIN
QUINIDINE POLYGALACTURONATE CARDIOQUIN
QUINIDINE SULFATE QUINIDEX, CIN-QIN,
QUINORA
QUININE SULFATE QUINAMM
RAUWOLFIA SERPENTINA RAUDIXIN, RAUVAL
RESCINNAMINE MODERIL
RESERPIN SERPATE RESERPOID,
SANDRIL, SERPASIL
RESFRPINE & HYDRALAZINE HYDROCHLORIDE SERPASIL -APRESOLINE
RESERPINE & HYDROCHLOROTHIAZIDE SERPASIL -ESIDRIX
SPIRONOLACTONE ALDACTONE
SPIRONOLACTONE W/HYDROGHLOROTHIAZIDE ALDACTAZIDE
SYRINGES (INSULIN)
SYROSINGOPINE & HYOROCHLOROTHIAZIDE SINGOSERP-ESIDRIX
TIMOLOL MALEATE, MSD BLOCADREN
TIMOLOL MALEATE & HYDROCHLOROTHIAZIDE, MSD TIMOLIDE
TOCAINIDE HYCROCHLOROTHIAZIDE, MSD TONOCARD
TOLAZIMIDE TOLINASE
TOLBUTAMIDE ORINASE
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TRALNITRATE PHOSPRATE METAMINE
TRIAMTERENE DYRENIUM
TRIAMTERENE & HYDROCHLOROTHIAZIDE DYAZIDE, MAXZIDE
TRICHLORMETHIAZIDE METAHYDRIN, DIURESE,
NAQUA, SPENZIDE
TRICHLORMETHIAZIDE & RESERPINE METATENSIN. NAQUIVAL
VERAPAMIL HYDROCHLORIDE CALAN, ISOPTEN
WARFARIN SODIUM COUMADIN
ARTHRITIC DRUGS
ACETYLSALICYLIC ACID ZORPRIN, EASPRIN
ALLOPURINOL ZYLOPRIM
AURANOFIN RIDAURA
AUROTHIOGLUCOSE SOLGANOL
AZATHIOPRINE IMURAN
COLCHICINE COLCHICINE
DICLOFENAC SODIUM VOLTAREN
DIFLUNISAL DOLOBID
ETODOLAC LODINE
FENOPROFEN CALCIUM NALFON
FLURBIPROFEN ANSAID
GOLD SODIUM THIOMALATE MYOCHRYSINE
HYDROXYCHLOROQUINE SULFATE PLAQUENIL
IBUPROFEN RUFEN, MOTRIN
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INDOMETHACIN INDOCIN
KETOPROFEN ORUDIS
MECLOFENAMATE SODIUM MECLOMIN
METHOTREXATE METHOTREXATE
NABUMETOME RELAFEN
NAPROXEN ANAPROX, NAPROSYN
PENICILLAMINE CUPRIMINE
PHENYLBUTAZONE BUTAZOLIDIN
PIROXICAM FELDENE
PREDNISONE DELTASONE
PROBENECID BENEMID
PROBENECID W/COLCHICINE COLBENEMID, PROBEN-C
SALSALATE DISALCID
SULINDAC CLINORIL
TOLMETIN SODIUM TOLECTIN, TOLECTIN DS
SALICYLATE COMBINATION TRILISATE
COPD DRUGS
ALBUTEROL PROVENTIL, VENTOLIN
AMINOPHYLLIN
BECLOMETHASONE DIPROPIONATE BECLOVENT, VANCERIL
BITOLTEROL MESYLATE TORNALATE
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CROMOLYN SODIUM INTAL, NASAL CROM
ETHYLNOREPINEPHRINE HCL BRONKEPHRINE
FLUNISOLIDE AEROBID
IPRATROPIUM BROMIDE ATROVENT
ISOETHARINE HCL BRONKOMETER,
BRONROSOL
ISOPROTERENOL ISUPREL,
MEDIHALER-ISO
ISOPROTERENOL & PHENYLEPHRINE BITARTRATE DUO-MEDIHALER
ISOPROTERENOL HCL NORISODRINE
ISOPROTERENOL HCL & CYCLOPENTAMINE AEROLONE
ISOPROTERENOL SULFATE & CALCIUM IODIDE NORISODRINE
 W/CALCIUM IODIDE
METAPROTERENOL SULFATE ALUPENT, METAPREL
OXYTRIPHYLLINE CHOLEDYL
PIRBUTEROL ACETATE MAXAIR
TERBUTALINE SULFATE  BRETHAIRE BRETHINE
THEOPHYLLINE CONSTANT-T,
RESPBID, SUSTAIRE
THEOPHYLLINE ANHYDROUS BRONKODDYL, THEO-24
THEOPHYLLINE ANHYDROUS-GUAIFENESIN THEOLATE,
ELIXOPHYLLIN GG
TRIAMCINOLONE ACETONIDE AZMACORT
NASAL PRODUCTS NOT COVERED.
G:\OPLALHS\LHSSTUD\ELDDRUGS\DRUGS.DOC 11/19/97
1997 Federal Poverty Guidelines for All States (Except Alaska and Hawaii)
 and the District of Columbia
Size of Percent of Federal Poverty Guideline Level
Family Unit 100% 125% 133% 150% 185%
1 $7,890 $9,863 $10,494 $11,835 $14,597
2 $10,610 $13,263 $14,111 $15,915 $19,629
3 $13,330 $16,663 $17,729 $19,995 $24,661
4 $16,050 $20,063 $21,347 $24,075 $29,693
5 $18,770 $23,463 $24,964 $28,155 $34,725
6 $21,490 $26,863 $28,582 $32,235 $39,757
7 $24,210 $30,263 $32,199 $36,315 $44,789
8 $26,930 $33,663 $35,817 $40,395 $49,821
For family units with more than 8 members, add $2,720 at 100% for each
 additional member.  (The same increment applies to smaller family sizes also,
 as can be seen in the figures above.)
Source: Federal Register , Vol. 62, No. 46, March 10, 1997,
pp. 10856-10859.
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TASK FORCE ON
IMPROVING ACCESS TO PRESCRIPTION DRUGS FOR THE
ELDERLY
PL 1997, Chapter 560, Part E
Members:
Sen. Chellie Pingree, Chair Jean Deyoe
Rep. Joseph Brooks Roger Hare
Rep. Robert Cameron John Grotton
Rep. Joseph Jabar John Marvin
Robert Philbrook
February 13, 1998
Senator Lloyd P. LaFountain III, Senate Chair
Representative Jane W. Saxl, House Chair
Joint Standing Committee on Banking and Insurance
118th Maine Legislature
Senator Judy A. Paradis, Senate Chair
Representative J. Elizabeth Mitchell, House Chair
Joint Standing Committee on Health and Human Services
118th Maine Legislature
re: Insurance coverage for organ transplant patients
Dear Sen. LaFountain, Sen. Paradis, Rep. Saxl and Rep. Mitchell:
In the course of our stdy on improving access to prescription drugs for the
elderly, we were dismayed to learn that there is inadequate insurance availability for organ
transplants patients.  As you may be aware, organ transplant patients require anti-rejection
medication for the rest of their lives.  Although our Task Force recommendation is to
provide coverage for elderly Mainers at or below 185% of the federal poverty level
through a Medicaid waiver program, neither the current Elderly Low-cost Drug Program
nor Medicare cover anti-rejection medication.  We enclose a letter from Alice Knapp of
the Bureau of Insurance explaining why the recent amendments to the community rating
law have negatively affected transplant patients, thus creating an enormous burden for
these patients and their families.
We understand that Massachusetts has adopted legislation requiring additional
coverage for prescription drugs.  The Bureau of Insurance is continuing to do research on
the Massachusetts program, whether it could be implemented in Maine, and whether it
makes sense to adopt the program here.
We respectfully request that the Banking and Insurance Committee and the Health
and Human Services Committee work with the Bureau of Insurance to develop methods
of providing financial assistance or insurance coverage for prescription drugs for organ
transplant patients in this State.
Thank you for your work on this issue that is devastating for a growing population
in our State.
Sincerely,
Sen. Chellie Pingree
Chair
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enclosure
cc: Maine Congressional delegation
Alice Knapp, Bureau of Insurance
